<p>Aura Biosciences, Inc.（纳斯达克代码：AURA - 获取免费报告）内部人士 Conor Kilroy 于 4 月 16 日（星期三）出售了 7,162 股公司股票。该股票以平均价格 5.49 美元出售，总价值为 39,319.38 美元。出售后，该内部人士现在持有 179,313 股公司股票，价值为 984,428.37 美元。这代表其持股比例下降了 3.84%。此次出售已在与证券交易委员会的法律文件中披露，您可以通过此链接访问。</p>
<p>获取 <strong>Aura Biosciences</strong> 警报：</p>
<h2>Aura Biosciences 股价下跌 3.1%</h2>
<ul>
<li>3 只小盘股准备实现显著增长</li>
</ul>
<p>在周三的交易时段，纳斯达克：AURA 股价下跌 0.17 美元，跌至 5.40 美元。该股票的交易量为 138,043 股，而其平均交易量为 200,409 股。该公司的 50 日简单移动平均为 6.85 美元，200 日简单移动平均为 8.23 美元。Aura Biosciences, Inc.的 1 年最低价为 3.40 美元，1 年最高价为 12.38 美元。该公司的市值为 2.7122 亿美元，市盈率为-3.12，贝塔值为 0.43。</p>
<p>Aura Biosciences（纳斯达克：AURA - 获取免费报告）最近于 3 月 24 日（星期一）发布了季度财报。该公司报告季度每股收益（EPS）为-0.52 美元，低于市场共识预期的-0.43 美元，差距为-0.09 美元。研究分析师预计 Aura Biosciences, Inc.在当前财政年度将发布-1.66 的每股收益。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者最近调整了对该公司的持股。Long Focus Capital Management LLC 在第四季度将其在 Aura Biosciences 的持股增加了 123.9%。Long Focus Capital Management LLC 现在拥有 2,537,774 股公司股票，价值 20,861,000 美元，在上个季度购买了 1,404,228 股。Vanguard Group Inc.在第四季度将其在 Aura Biosciences 的持股增加了 6.2%。Vanguard Group Inc.现在拥有 1,917,730 股公司股票，价值 15,764,000 美元，在上个季度购买了 112,296 股。Franklin Resources Inc.在第四季度将其在 Aura Biosciences 的持股增加了 3.2%。Franklin Resources Inc.现在拥有 1,723,063 股公司股票，价值 14,164,000 美元，在上个季度购买了 54,103 股。Levin Capital Strategies L.P.在第四季度将其在 Aura Biosciences 的持股增加了 169.1%。Levin Capital Strategies L.P.现在拥有 1,247,619 股公司股票，价值 10,255,000 美元，在上个季度购买了 783,984 股。最后，Geode Capital Management LLC 在第四季度将其在 Aura Biosciences 的持股增加了 0.4%。Geode Capital Management LLC 现在拥有 1,012,799 股公司股票，价值 8,327,000 美元，在上个季度购买了 3,972 股。机构投资者和对冲基金持有该公司 96.75% 的股票。</p>
<h2>分析师评级变动</h2>
<p>一些分析师最近对该公司发布了报告。JMP Securities 在 3 月 26 日（星期三）的报告中将 Aura Biosciences 的目标价格设定为 19.00 美元。HC Wainwright 在 3 月 25 日（星期二）的研究报告中将 Aura Biosciences 的目标价格设定为 25.00 美元。花旗集团在 3 月 26 日（星期三）的研究报告中重申了对 Aura Biosciences 的 “跑赢大盘” 评级。最后，Lifesci Capital 在 1 月 31 日（星期五）的研究报告中将 Aura Biosciences 的评级提升至 “强力买入”。六位研究分析师对该股票给予了买入评级，两位分析师给予了强力买入评级。根据 MarketBeat.com 的数据，Aura Biosciences 目前的共识评级为 “买入”，共识目标价格为 22.75 美元。</p>
<p><strong>阅读我们对 Aura Biosciences 的最新分析</strong></p>
<h2>关于 Aura Biosciences</h2>
<p>（获取免费报告）</p>
<p>Aura Biosciences, Inc.是一家临床阶段的生物技术公司，开发精准免疫疗法以治疗多种实体肿瘤。该公司的专有平台能够通过与药物结合或装载核酸的类病毒颗粒，针对多种实体肿瘤，创造类病毒药物结合物。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Aura Biosciences</li>
<li>使用 MarketBeat 股票拆分计算器</li>
<li>Viking Therapeutics 股票上涨但难以保持涨幅</li>
<li>市值计算器：如何计算市值</li>
<li>高通股票刚刚获得新的买入评级——值得期待</li>
<li>什么是热门股票？热门股票的解释</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVVSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVVSQQ"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Aura Biosciences 吗？</h2>
<p>在考虑 Aura Biosciences 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Aura Biosciences 并不在名单上。</p>
<p>虽然 Aura Biosciences 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AURA

<p>Aura Biosciences, Inc. 的内部人士 Conor Kilroy 以每股 5.49 美元的价格出售了 7,162 股，总计 39,319.38 美元，减少了 3.84% 的持股比例。出售后，他持有 179,313 股，估值约为 984,428.37 美元。该股票下跌 3.1%，报 5.40 美元，市值为 2.7122 亿美元。分析师设定的共识目标价为 22.75 美元，大多数分析师给予该股票 “买入” 评级</p>

<p>Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) insider Conor Kilroy sold 7,162 shares of the company's stock in a transaction dated Wednesday, April 16th. The stock was sold at an average price of $5.49, for a total value of $39,319.38. Following the sale, the insider now owns 179,313 shares of the company's stock, valued at $984,428.37. This represents a 3.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink.</p>
<div class="lb-trans"><p>Aura Biosciences, Inc.（纳斯达克代码：AURA - 获取免费报告）内部人士 Conor Kilroy 于 4 月 16 日（星期三）出售了 7,162 股公司股票。该股票以平均价格 5.49 美元出售，总价值为 39,319.38 美元。出售后，该内部人士现在持有 179,313 股公司股票，价值为 984,428.37 美元。这代表其持股比例下降了 3.84%。此次出售已在与证券交易委员会的法律文件中披露，您可以通过此链接访问。</p>
</div><p>Get <strong>Aura Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Aura Biosciences</strong> 警报：</p>
</div><h2>Aura Biosciences Trading Down 3.1 %</h2>
<div class="lb-trans"><h2>Aura Biosciences 股价下跌 3.1%</h2>
</div><ul>
<li>3 Small-Cap Stocks Ready to Deliver Significant Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只小盘股准备实现显著增长</li>
</ul>
</div><p>NASDAQ:AURA traded down $0.17 during trading hours on Wednesday, hitting $5.40. The stock had a trading volume of 138,043 shares, compared to its average volume of 200,409. The business has a 50 day simple moving average of $6.85 and a two-hundred day simple moving average of $8.23. Aura Biosciences, Inc. has a 1-year low of $3.40 and a 1-year high of $12.38. The company has a market cap of $271.22 million, a PE ratio of -3.12 and a beta of 0.43.</p>
<div class="lb-trans"><p>在周三的交易时段，纳斯达克：AURA 股价下跌 0.17 美元，跌至 5.40 美元。该股票的交易量为 138,043 股，而其平均交易量为 200,409 股。该公司的 50 日简单移动平均为 6.85 美元，200 日简单移动平均为 8.23 美元。Aura Biosciences, Inc.的 1 年最低价为 3.40 美元，1 年最高价为 12.38 美元。该公司的市值为 2.7122 亿美元，市盈率为-3.12，贝塔值为 0.43。</p>
</div><p>Aura Biosciences (NASDAQ:AURA - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.09). Research analysts expect that Aura Biosciences, Inc. will post -1.66 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Aura Biosciences（纳斯达克：AURA - 获取免费报告）最近于 3 月 24 日（星期一）发布了季度财报。该公司报告季度每股收益（EPS）为-0.52 美元，低于市场共识预期的-0.43 美元，差距为-0.09 美元。研究分析师预计 Aura Biosciences, Inc.在当前财政年度将发布-1.66 的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors have recently modified their holdings of the business. Long Focus Capital Management LLC increased its holdings in Aura Biosciences by 123.9% during the 4th quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company's stock worth $20,861,000 after purchasing an additional 1,404,228 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Aura Biosciences by 6.2% during the fourth quarter. Vanguard Group Inc. now owns 1,917,730 shares of the company's stock worth $15,764,000 after buying an additional 112,296 shares in the last quarter. Franklin Resources Inc. grew its position in shares of Aura Biosciences by 3.2% during the fourth quarter. Franklin Resources Inc. now owns 1,723,063 shares of the company's stock worth $14,164,000 after buying an additional 54,103 shares in the last quarter. Levin Capital Strategies L.P. increased its stake in shares of Aura Biosciences by 169.1% in the fourth quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company's stock worth $10,255,000 after buying an additional 783,984 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Aura Biosciences by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company's stock valued at $8,327,000 after acquiring an additional 3,972 shares in the last quarter. Institutional investors and hedge funds own 96.75% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近调整了对该公司的持股。Long Focus Capital Management LLC 在第四季度将其在 Aura Biosciences 的持股增加了 123.9%。Long Focus Capital Management LLC 现在拥有 2,537,774 股公司股票，价值 20,861,000 美元，在上个季度购买了 1,404,228 股。Vanguard Group Inc.在第四季度将其在 Aura Biosciences 的持股增加了 6.2%。Vanguard Group Inc.现在拥有 1,917,730 股公司股票，价值 15,764,000 美元，在上个季度购买了 112,296 股。Franklin Resources Inc.在第四季度将其在 Aura Biosciences 的持股增加了 3.2%。Franklin Resources Inc.现在拥有 1,723,063 股公司股票，价值 14,164,000 美元，在上个季度购买了 54,103 股。Levin Capital Strategies L.P.在第四季度将其在 Aura Biosciences 的持股增加了 169.1%。Levin Capital Strategies L.P.现在拥有 1,247,619 股公司股票，价值 10,255,000 美元，在上个季度购买了 783,984 股。最后，Geode Capital Management LLC 在第四季度将其在 Aura Biosciences 的持股增加了 0.4%。Geode Capital Management LLC 现在拥有 1,012,799 股公司股票，价值 8,327,000 美元，在上个季度购买了 3,972 股。机构投资者和对冲基金持有该公司 96.75% 的股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of analysts have recently issued reports on the company. JMP Securities set a $19.00 target price on Aura Biosciences in a report on Wednesday, March 26th. HC Wainwright set a $25.00 price objective on shares of Aura Biosciences in a research note on Tuesday, March 25th. Citigroup reissued an &#34;outperform&#34; rating on shares of Aura Biosciences in a research note on Wednesday, March 26th. Finally, Lifesci Capital raised shares of Aura Biosciences to a &#34;strong-buy&#34; rating in a research report on Friday, January 31st. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Aura Biosciences presently has a consensus rating of &#34;Buy&#34; and a consensus target price of $22.75.</p>
<div class="lb-trans"><p>一些分析师最近对该公司发布了报告。JMP Securities 在 3 月 26 日（星期三）的报告中将 Aura Biosciences 的目标价格设定为 19.00 美元。HC Wainwright 在 3 月 25 日（星期二）的研究报告中将 Aura Biosciences 的目标价格设定为 25.00 美元。花旗集团在 3 月 26 日（星期三）的研究报告中重申了对 Aura Biosciences 的 “跑赢大盘” 评级。最后，Lifesci Capital 在 1 月 31 日（星期五）的研究报告中将 Aura Biosciences 的评级提升至 “强力买入”。六位研究分析师对该股票给予了买入评级，两位分析师给予了强力买入评级。根据 MarketBeat.com 的数据，Aura Biosciences 目前的共识评级为 “买入”，共识目标价格为 22.75 美元。</p>
</div><p><strong>Read Our Latest Analysis on Aura Biosciences</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Aura Biosciences 的最新分析</strong></p>
</div><h2>About Aura Biosciences</h2>
<div class="lb-trans"><h2>关于 Aura Biosciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.</p>
<div class="lb-trans"><p>Aura Biosciences, Inc.是一家临床阶段的生物技术公司，开发精准免疫疗法以治疗多种实体肿瘤。该公司的专有平台能够通过与药物结合或装载核酸的类病毒颗粒，针对多种实体肿瘤，创造类病毒药物结合物。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Aura Biosciences</li>
<li>Using the MarketBeat Stock Split Calculator</li>
<li>Viking Therapeutics Stock Pops But Struggles to Hold Gains</li>
<li>Market Cap Calculator: How to Calculate Market Cap</li>
<li>Qualcomm Stock Just Earned a Fresh Buy Rating—Get Excited</li>
<li>What Are Trending Stocks? Trending Stocks Explained</li>
<li>Meta Stock Holds Upside Potential as Analysts Cut Price Targets</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Aura Biosciences</li>
<li>使用 MarketBeat 股票拆分计算器</li>
<li>Viking Therapeutics 股票上涨但难以保持涨幅</li>
<li>市值计算器：如何计算市值</li>
<li>高通股票刚刚获得新的买入评级——值得期待</li>
<li>什么是热门股票？热门股票的解释</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVVSQQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=AURA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Aura Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Aura Biosciences 吗？</h2>
</div><p>Before you consider Aura Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Aura Biosciences 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Aura Biosciences 并不在名单上。</p>
</div><p>While Aura Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Aura Biosciences 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Aura Biosciences, Inc. (NASDAQ:AURA) 的内部人士 Conor Kilroy 出售了 7,162 股股票